For An Ultra-High-Priced Drug, Alnylam Brings A New Idea
The company will launch Givlaari with a novel prevalence-based adjustment feature for payers, which will trigger higher rebates if the number of diagnosed patients is higher than expected.
You may also be interested in...
Alnylam’s short-interfering RNA, Givlaari, has become the first treatment to be approved for preventing attacks of acute hepatic porphyria in the EU, and Alnylam wants to pursue a value-based agreement framework to accelerate patient and provider access.
Interaction with the European Medicines Agency on Givlaari helped Alnylam prepare a more robust application package to demonstrate the medicine’s benefits and risks.
The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.